Board of Advisors

Board of Advisors

Charles (“Chip”) N. Kahn, III

Charles (“Chip”) N. Kahn, III is President of the Federation of American Hospitals, the national advocacy organization for investor-owned hospitals and health systems. Mr. Kahn is one of the nation’s preeminent experts on health policy and Medicare issues, and his leadership on health care issues and in the political arena is well-recognized. Since becoming President of the Federation, he has appeared every year on the “100 Most Powerful People in Healthcare” list published by Modern Healthcare magazine. In April 2006, The Hill newspaper selected him as one of the capital’s top trade association lobbyists for the sixth consecutive year. Mr. Kahn also has been acknowledged as one of two “major movers” of an effort sponsored by the Robert Wood Johnson Foundation to bring together a diverse coalition of major national advocacy organizations to seek solutions to extending health coverage to the uninsured. 

Harvey C. Sigelbaum, Esq.

Harvey C. Sigelbaum, Senior Advisor to the Riverside Company, a large private equity firm, has over 30 years’ experience as CEO of large insurance companies. From 1996 to 2006, Mr. Sigelbaum served as president and co-CEO, as well as vice chairman and then executive chairman, of MultiPlan, Inc., one of the country’s largest health care network organizations. Previously, Mr. Sigelbaum worked for 17 years as president and CEO of Amalgamated Life Insurance Company. Prior to that he was president and CEO of Urban Community Insurance Company, a New York domiciled, “A” rated regional insurer. Mr. Sigelbaum has been active on a number of boards, including service as chairman of the National Cooperative Bank, a Washington, D.C.-based national bank for cooperatives; chairman, National Cooperative Business Association; and chairman, National Association on Drug Abuse Problems. Other board work included executive committee, America’s Health Insurance Plans; executive committee, Council for Affordable Quality Healthcare; Life Insurance Council of New York; New York Urban Coalition; Americas Association of Cooperative/Mutual Insurance Societies (International Cooperative & Mutual Insurance Federation); and the Overseas Cooperative Development Council. He was recently named to the Ambassadors Council of Freedom from Hunger. Appointed by President Clinton in 1994, Mr. Sigelbaum was confirmed to this position by the U.S. Senate.

Howard Fillit, M.D.

Howard Fillit, M.D., is the founding Executive Director of the Alzheimer’s Drug Discovery Foundation and the Institute for the Study of Aging (ISOA), biomedical venture philanthropy foundations advancing drug discovery for Alzheimer’s disease, related dementias and cognitive aging. A geriatrician and neuroscientist, Dr. Fillit has over 25 years of experience in the Alzheimer’s and cognitive aging field, and is currently clinical professor of geriatrics and medicine, and professor of neurobiology at The Mount Sinai School of Medicine (NY). Prior to founding ISOA, Dr. Fillit was the Corporate Medical Director for Medicare at New York Life, responsible for over 125,000 Medicare members in 8 regional markets. He has received numerous awards, including the Alzheimer’s Association’s Rita Hayworth Award, and is the author of more than 200 scientific articles, abstracts and books including the leading international Textbook of Geriatric Medicine and Gerontology. Dr. Fillit also serves as a speaker and consultant for the pharmaceutical and biotechnology industries. 

Dan Dragalin, M.D.

Dan Dragalin, M.D. is Medical Director at McKesson and was formerly Chief Medical Officer of HIP, Health Insurance Plan of New York. Prior to joining HIP in January 2007, Dr. Dragalin was responsible for development and maintenance of the MultiPlan PPO national network, comprised of 4,600 hospitals, 100,000 ancillary facilities and over 500,000 practitioners. Prior to joining MultiPlan, Dr. Dragalin served as the President of the Northeast Region of Great West Life (One Health Plan), as national Medical Director for One Health Plan, and as the President of the Atlantic Region of the New York Life Insurance Company’s subsidiary, NYLCare. Prior to that position, he was the President of HMO Blue, the managed care subsidiary of Blue Cross/Blue Shield of New Jersey, and was the Vice President, Healthcare Operations and Research for the Prudential Insurance Company of America. Dr. Dragalin has served as the Health Insurance Association of America representative on the American Medical Association’s CPT-4 Editorial Panel; he has also served on the Physician Payment Review Commission’s Consensus Panel on Coding, and on the Advisory Committee for the Foundation for Health Services Research. He has served on the Board of Directors of the National Committee on Quality Assurance and on numerous technical committees including The Technical Experts Group of the Hospital Research and Educational Trust, the Managed Health Care Association Task Force on Outcomes, the Center for Drug Abuse Services Research Advisory Committee, and the Managed Care Task Force of the Joint Commission. 

Jeffrey L. Cummings, M.D.

Jeffrey L. Cummings, M.D., Sc.D. is Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. He is the Camille and Larry Ruvo Chair for Brain Health of the Neurological Institute of Cleveland Clinic. The Lou Ruvo Center for Brain Health is a clinical care, translational research, and clinical trials enterprise specializing in care of patients with neurocognitive deficits and development of new therapies for neurodegenerative disorders. Dr. Cummings is an experienced clinical trialist with expertise in clinical trial design and analysis, global trial implementation, and trial outcome measures. Dr. Cummings is the author of the Neuropsychiatric Inventory (NPI) which is the most commonly used tool for clinical trials characterizing behavioral disturbances in dementia syndromes. Dr. Cummings completed Neurology residency and a Fellowship in Behavioral Neurology at Boston University, Boston, Massachusetts. US training was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England. Dr. Cummings was formerly Professor of Neurology and Psychiatry at UCLA, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cummings has authored or edited over 30 books and published 600 peer-reviewed papers. 

Paula Tallal, Ph.D.

Paula Tallal, Ph.D. is a founder and director of Scientific Learning Corporation (NASDAQ: SCIL) and a world-recognized authority on language-learning disabilities. A cognitive neuroscientist and a board-certified clinical psychologist, she is a founder and co-director of the Center for Molecular and Behavioral Neuroscience at Rutgers University. In addition, she is active on many scientific advisory boards and government committees for both developmental language disorders and learning problems. Dr. Tallal has over 20 years’ experience managing multi-site, multi-disciplinary, federally funded contracts and grants that have resulted in over 150 publications as well as national and international honors. She has received Rutgers’ highest academic award, Rutgers University Board of Trustees Award for Excellence in Research and holds the University’s highest academic rank, Distinguished Professor II. Dr. Tallal has recently been appointed Rutgers University, Board of Governors Professor of Neuroscience. In 1996, Dr. Tallal co-founded the Scientific Learning Corporation, a neuroscience company dedicated to developing and delivering research-based, cognitive and educational programs, where she currently serves on the Board. She is the co-inventor on several U.S. patents, for which she won the Thomas Alva Edison Patent Award in 2000. 

Gene Huang

Gene Huang, who recently joined Remedy Partners, has held senior management positions with managed care companies for the past 25 years. He was VP of Aveta, Inc., a Medicare managed care company, and Vice President of Health Net’s Senior Product Division. Prior positions included Senior Vice President of Alliance Health Card, and Vice President of Health Facilitation of CIGNA Healthcare. Of his notable achievements, while Vice President of Oxford Health Plans, Mr. Huang was responsible for building one of the nation’s fastest growing Medicare HMOs. 

Allen M. Greenberg

Mr. Greenberg has served as legal counsel to technology companies in the United States and in Israel. He was the Advisor for Legal and Regulatory Affairs at NeuroTrax before joining Ex Libris as General Counsel. Previously, he was the General Counsel of 3M Health Information Systems, Inc., a subsidiary of 3M Company, and prior to that, General Counsel of SoftMed Systems, Inc. In recent years, Mr. Greenberg’s work has included healthcare technology transactions and other commercial contracts, including software licensing, distribution and professional services agreements. Earlier in his career, Mr. Greenberg practiced in the area of corporate and securities law. Mr. Greenberg earned a BA magna cum laude from Harvard, a JD from the University of Pennsylvania and an MBA jointly from Tel Aviv University and Northwestern University.

"It offers concrete data that can help identify which spheres of cognition are being affected."

“Allows easier access to cognitive assessments with good efficacy in a reasonable time frame."

“Longitudinal follow up with repeat testing sessions is also one of its strengths.”

“It's a peer-reviewed test that provides results that can be used to help improve care.”

“It allows for numeric and graphic comparisons both to 'normal' scores and also previous tests of same individual.”

“It lends the examiner credence when showing the results "in black and white.”

“Allows a more objective cognitive assessment and the results are often not obvious on interview.”

“This is a valuable tool that gives insight into current cognitive levels."

“Results are immediately available and the data can be instantly absorbed."

“People of a wide age range are able to perform this test with minimal to no computer knowledge.”

“… people appreciate having a time-efficient method of evaluating their cognition.”

“It's a convenient, on-site tool that provides a snapshot with a fair level of detail pertaining to one's cognitive abilities.”

“Provides a convenient, objective, cognitive assessment at low cost.”

“It is easy to use - it can be very time savvy”

“A more objective assessment of cognitive function”

“Good tool for establishing a baseline and tracking progress.”

“It creates an objective report.”

Innovative Science for Brain Health